TapewireFind a company

person · Reporting owner

Bedoya-Toro Munera Maria E

Disclosed activity across 1 company

Tapewire entity
60030
SEC CIK
0001400048

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Dermata Therapeutics, Inc.DRMA · Entity 8182SVP, Regulatory AffairsFebruary 17, 2026March 17, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dermata Therapeutics, Inc.

Report date February 17, 2026 · Filed March 17, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,012 Reported balance After 2026-02-17 transaction · row 1
1 source row

Row 1 · 2026-02-17 · Purchase · Acquired 1,000 · Balance 1,012

Common StockSEC Table I · non-derivativeIndirectMunera Family Trust34 Reported balance Holding disclosure · report date 2026-02-17 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 34

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 17, 2026 Filed Mar 17, 2026 21:44 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 PurchaseCommon Stock 1,000 $1.27 $1,270.00
Disclosure

SEC source: 0001493152-26-010630 · ownership.xml · nonDerivative · entry 1

Bedoya-Toro Munera Maria E · CIK 0001400048 · SVP, Regulatory Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,012

Read SEC document
January 02, 2026 Filed Jan 7, 2026 01:00 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 GrantStock Option (right to buy) · Derivative 9,000 $0.00 Strike: $2.18 $0.00
Disclosure

SEC source: 0001493152-26-000704 · ownership.xml · derivative · entry 1

Bedoya-Toro Munera Maria E · CIK 0001400048 · SVP, Regulatory Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date.

Read SEC document
January 13, 2025 Filed Jan 14, 2025 23:56 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 GrantStock Option (right to buy) · Derivative 8,000 $0.00 Strike: $1.38 $0.00
Disclosure

SEC source: 0001654954-25-000411 · section16.xml · derivative · entry 1

Bedoya-Toro Munera Maria E · CIK 0001400048 · SVP, Regulatory Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2035-01-12

F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date.

Read SEC document
January 04, 2024 Filed Jan 6, 2024 02:00 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 GrantStock Option (right to buy) · Derivative 25,000 $0.00 Strike: $0.61 $0.00
Disclosure

SEC source: 0001654954-24-000290 · section16.xml · derivative · entry 1

Bedoya-Toro Munera Maria E · CIK 0001400048 · SVP, Regulatory Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-01-03

F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12-month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12-month anniversary of the grant date.

Read SEC document
January 03, 2023 Filed Jan 5, 2023 21:06 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 GrantStock Option (right to buy) · Derivative 50,000 $0.00 Strike: $0.31 $0.00
Disclosure

SEC source: 0001654954-23-000148 · section16.xml · derivative · entry 1

Bedoya-Toro Munera Maria E · CIK 0001400048 · SVP, Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-01-02

F1 · derivative.exercise_date: The shares underlying the option will vest as to 25% upon the 12 month anniversary of the grant date, and will vest as to 75% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date.

Read SEC document
January 03, 2022 Filed Jan 5, 2022 23:59 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $1.88 $0.00
Disclosure

SEC source: 0000905718-22-000038 · dermata_fm4jan32022.xml · derivative · entry 1

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-01-02

F1 · derivative.exercise_date: The option will vest as to 40% upon the 12 month anniversary of the grant date, and will vest as to 60% in 36 equal monthly installments commencing on the 12 month anniversary of the grant date

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionWarrant to Purchase Common Stock · Derivative 4,878 $0.00 Strike: $20.50 $0.00
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 13

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 4,878

Underlying: Common Stock · 4,878 shares

Expires 2026-03-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionSeries 1a Warrants · Derivative 100,000 $0.00 $0.00
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 12

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 4,878 shares

Expires 2026-03-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionSeries 1 Preferred Stock · Derivative 280,000 $0.00 $0.00
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 11

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 13,658 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.

F5 · derivative.exercise_date: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.

F5 · derivative.expiration_date: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionSeries 1c Preferred Stock · Derivative 357,142 $0.00 $0.00
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 10

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 17,421 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.

F4 · derivative.exercise_date: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.

F4 · derivative.expiration_date: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionSeries 1b Preferred Stock · Derivative 100,000 $0.00 $0.00
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 9

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 4,878 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.

F3 · derivative.exercise_date: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.

F3 · derivative.expiration_date: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionSeries 1a Preferred Stock · Derivative 400,000 $0.00 $0.00
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 8

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 19,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.

F2 · derivative.exercise_date: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.

F2 · derivative.expiration_date: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionSeries 1d Preferred Stock · Derivative 61,821 $0.00 $0.00
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · derivative · entry 7

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 0

Underlying: Common Stock · 9,162 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.

F1 · derivative.exercise_date: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.

F1 · derivative.expiration_date: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionCommon Stock 13,658 Not disclosed Not disclosed
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · nonDerivative · entry 5

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 84,143

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionCommon Stock 17,421 Not disclosed Not disclosed
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · nonDerivative · entry 4

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 70,485

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionCommon Stock 4,878 Not disclosed Not disclosed
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · nonDerivative · entry 3

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 53,064

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionCommon Stock 19,512 Not disclosed Not disclosed
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · nonDerivative · entry 2

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 48,186

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document
August 17, 2021 Filed Aug 17, 2021 16:51 UTC Dermata Therapeutics, Inc. DRMA · Entity 8182 ConversionCommon Stock 9,162 Not disclosed Not disclosed
Disclosure

SEC source: 0000905718-21-001112 · dermata_fm4aug172021.xml · nonDerivative · entry 1

Bedoya-Toro Munera Maria E · CIK 0001400048 · Senior Vice President

10b5-1 filing: Not disclosed

Ownership: Indirect · By Munera Family Trust

Disclosed balance after: 28,674

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.

F7 · ownership.nature: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.